177 related articles for article (PubMed ID: 24505234)
1. Anti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar.
Shi J; Fan D; Dong C; Liu H; Jia B; Zhao H; Jin X; Liu Z; Li F; Wang F
Theranostics; 2014; 4(3):256-66. PubMed ID: 24505234
[TBL] [Abstract][Full Text] [Related]
2. Two ⁹⁰Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy.
Liu Z; Shi J; Jia B; Yu Z; Liu Y; Zhao H; Li F; Tian J; Chen X; Liu S; Wang F
Mol Pharm; 2011 Apr; 8(2):591-9. PubMed ID: 21247151
[TBL] [Abstract][Full Text] [Related]
3. Targeted radionuclide therapy with RAFT-RGD radiolabelled with (90)Y or (177)Lu in a mouse model of αvβ3-expressing tumours.
Bozon-Petitprin A; Bacot S; Gauchez AS; Ahmadi M; Bourre JC; Marti-Batlle D; Perret P; Broisat A; Riou LM; Claron M; Boturyn D; Fagret D; Ghezzi C; Vuillez JP
Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):252-63. PubMed ID: 25164771
[TBL] [Abstract][Full Text] [Related]
4. Imaging integrin α(v)β(3) positive glioma with a novel RGD dimer probe and the impact of antiangiogenic agent (Endostar) on its tumor uptake.
Wu H; Chen H; Sun Y; Wan Y; Wang F; Jia B; Su X
Cancer Lett; 2013 Jul; 335(1):75-80. PubMed ID: 23403076
[TBL] [Abstract][Full Text] [Related]
5. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive detection of human-induced pluripotent stem cell (hiPSC)-derived teratoma with an integrin-targeting agent (99m)Tc-3PRGD2.
Li Y; Liu Z; Dong C; He P; Liu X; Zhu Z; Jia B; Li F; Wang F
Mol Imaging Biol; 2013 Feb; 15(1):58-67. PubMed ID: 22707047
[TBL] [Abstract][Full Text] [Related]
7. Palmitic Acid-Conjugated Radiopharmaceutical for Integrin α
Yang G; Gao H; Luo C; Zhao X; Luo Q; Shi J; Wang F
Pharmaceutics; 2022 Jun; 14(7):. PubMed ID: 35890224
[TBL] [Abstract][Full Text] [Related]
8. αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4.
Jin ZH; Furukawa T; Degardin M; Sugyo A; Tsuji AB; Yamasaki T; Kawamura K; Fujibayashi Y; Zhang MR; Boturyn D; Dumy P; Saga T
Mol Cancer Ther; 2016 Sep; 15(9):2076-85. PubMed ID: 27422811
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of
Zheng J; Miao W; Huang C; Lin H
Ann Nucl Med; 2017 Jul; 31(6):486-494. PubMed ID: 28474165
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
11. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
12. Tumor uptake of the RGD dimeric probe (99m)Tc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature.
Liu Z; Jia B; Shi J; Jin X; Zhao H; Li F; Liu S; Wang F
Bioconjug Chem; 2010 Mar; 21(3):548-55. PubMed ID: 20184307
[TBL] [Abstract][Full Text] [Related]
13. Study of novel molecular probe 99mTc-3PRGD2 in the diagnosis of rheumatoid arthritis.
Huang C; Zheng Q; Miao W
Nucl Med Commun; 2015 Dec; 36(12):1208-14. PubMed ID: 26352213
[TBL] [Abstract][Full Text] [Related]
14. The feasibility of 18F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with 18F-FDG.
Cui Y; Liu H; Liang S; Zhang C; Cheng W; Hai W; Yin B; Wang D
Oncotarget; 2016 May; 7(19):27243-54. PubMed ID: 27029065
[TBL] [Abstract][Full Text] [Related]
15. PET imaging of neovascularization with (68)Ga-3PRGD2 for assessing tumor early response to Endostar antiangiogenic therapy.
Shi J; Jin Z; Liu X; Fan D; Sun Y; Zhao H; Zhu Z; Liu Z; Jia B; Wang F
Mol Pharm; 2014 Nov; 11(11):3915-22. PubMed ID: 25158145
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of an Integrin α
Gai Y; Jiang Y; Long Y; Sun L; Liu Q; Qin C; Zhang Y; Zeng D; Lan X
Mol Pharm; 2020 Jan; 17(1):349-358. PubMed ID: 31829615
[TBL] [Abstract][Full Text] [Related]
17. Monitoring tumor response to linifanib therapy with SPECT/CT using the integrin αvβ3-targeted radiotracer 99mTc-3P-RGD2.
Ji S; Zhou Y; Voorbach MJ; Shao G; Zhang Y; Fox GB; Albert DH; Luo Y; Liu S; Mudd SR
J Pharmacol Exp Ther; 2013 Aug; 346(2):251-8. PubMed ID: 23750021
[TBL] [Abstract][Full Text] [Related]
18. 67Cu-Radiolabeling of a multimeric RGD peptide for αVβ3 integrin-targeted radionuclide therapy: stability, therapeutic efficacy, and safety studies in mice.
Jin ZH; Furukawa T; Ohya T; Degardin M; Sugyo A; Tsuji AB; Fujibayashi Y; Zhang MR; Higashi T; Boturyn D; Dumy P; Saga T
Nucl Med Commun; 2017 Apr; 38(4):347-355. PubMed ID: 28291159
[TBL] [Abstract][Full Text] [Related]
19. Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers.
Wang L; Shi J; Kim YS; Zhai S; Jia B; Zhao H; Liu Z; Wang F; Chen X; Liu S
Mol Pharm; 2009; 6(1):231-45. PubMed ID: 19067525
[TBL] [Abstract][Full Text] [Related]
20. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
